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high surgical risk, but complications can impact long-term outcomes. The Lotus valve, designed to improve upon earlier
devices, is fully repositionable and retrievable, with a unique seal to minimize paravalvular regurgitation (PVR).
OBJECTIVES The prospective, single-arm, multicenter REPRISE II study (REpositionable Percutaneous Replacement of
Stenotic Aortic Valve Through Implantation of Lotus Valve System: Evaluation of Safety and Performance) evaluated the
transcatheter valve system for treatment of severe symptomatic calciﬁc aortic valve stenosis.
METHODS Patients (n ¼ 120; aortic annulus 19 to 27 mm) considered by a multidisciplinary heart team to be at high
surgical risk received the valve transfemorally. The primary device performance endpoint, 30-day mean pressure
gradient, was assessed by an independent echocardiographic core laboratory and compared with a pre-speciﬁed
performance goal. The primary safety endpoint was 30-day mortality. Secondary endpoints included safety/effectiveness
metrics per Valve Academic Research Consortium criteria.
RESULTS Mean age was 84.4 years, 57% of the patients were female, and 76% were New York Heart Association
functional class III/IV. Mean aortic valve area was 0.7  0.2 cm2. The valve was successfully implanted in all patients, with
no cases of valve embolization, ectopic valve deployment, or additional valve implantation. All repositioning (n ¼ 26) and
retrieval (n ¼ 6) attempts were successful; 34 patients (28.6%) received a permanent pacemaker. The primary device
performance endpoint was met, because the mean gradient improved from 46.4  15.0 mm Hg to 11.5  5.2 mm Hg.
At 30 days, the mortality rate was 4.2%, and the rate of disabling stroke was 1.7%; 1 (1.0%) patient had moderate PVR,
whereas none had severe PVR.
CONCLUSIONS REPRISE II demonstrates the safety and effectiveness of the Lotus valve in patients with severe aortic
stenosis who are at high surgical risk. The valve could be positioned successfully with minimal PVR. (REPRISE II:
REpositionable Percutaneous Replacement of Stenotic Aortic Valve Through Implantation of Lotus Valve System -
Evaluation of Safety and Performance; NCT01627691) (J Am Coll Cardiol 2014;64:1339–48) © 2014 by the American
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1340A ortic stenosis is a major cause of car-diovascular morbidity and mortal-ity. Many patients with severe and
symptomatic aortic stenosis are successfully
treated with surgical aortic valve replace-
ment (1,2). For those deemed poor surgical
candidates (3), mortality after 1 year with
standard medical therapy may be as high
as 50% (4–6). Transcatheter aortic valve
replacement (TAVR) in patients unsuitable
for surgical aortic valve replacement has
reduced mortality (7,8), and treatment of
selected patients at high surgical risk has
resulted in similar (balloon-expandable
valve) (9) or better (self-expanding valve)
(10) 1-year survival. However, there remain
infrequent, speciﬁc, and signiﬁcant compli-
cations with TAVR that impact long-term
outcomes and may limit its use in lower-
risk patients (11,12). Precise valve positioningcan be challenging with currently available devices,
and valve misplacement can lead to severe complica-
tions, including coronary occlusion and valve embo-
lization (13). Incomplete apposition of the prosthesis
with the native valve can occur in the presence of
signiﬁcant amounts of calcium or with suboptimal
implantation, resulting in paravalvular regurgitation
(PVR) (14,15). This has been associated with in-
creased mortality in several longitudinal registries
(16–18).SEE PAGE 1349The Lotus Valve System incorporates several fea-
tures intended to improve upon ﬁrst-generation
transcatheter devices (19). The valve is fully reposi-
tionable and retrievable and has a unique adaptive
seal designed to minimize PVR. In the REPRISE I
feasibility study (REpositionable Percutaneousd consultant fees and honoraria from Edwards Lifesciences, Med
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plantation of Lotus Valve SystEm), valve implanta-
tion resulted in minimal aortic regurgitation, with
hemodynamic and clinical beneﬁts at 1-year follow-
up and a low rate of adverse events (20). We
describe here 30-day outcomes, the primary endpoint
in the prospective, single-arm, multicenter, 120-
patient REPRISE II CE-Mark study, which was de-
signed to assess safety and performance of this novel
system in patients at high risk for surgical interven-
tion. The study is registered at ClinicalTrials.gov
(unique identiﬁer NCT01627691).
METHODS
DEVICE DESCRIPTION. The Lotus Aortic Valve
Replacement System (Boston Scientiﬁc Corporation,
Marlborough, Massachusetts) has been described
previously (19). Brieﬂy, it includes a pre-attached
bioprosthetic bovine pericardial aortic valve moun-
ted within a woven nitinol wire frame and a catheter-
based system for introduction (Figure 1). In this study,
all implantations were performed via retrograde de-
livery via the femoral artery. The valve is expanded
via controlled mechanical expansion. Rapid pacing is
not required during valve deployment; the valve
functions early in the deployment cycle and can be
repositioned or fully retrieved at any point before
uncoupling and valve release (even when 100%
expanded). An outer adaptive seal is designed to
minimize PVR. Two valve sizes, 23 mm and 27 mm,
were available for this study.
PATIENT SELECTION. Enrolled patients had symp-
tomatic (New York Heart Association [NYHA] func-
tional class II or greater) severe calciﬁc aortic valve
stenosis documented by transthoracic echocardiog-
raphy (TTE) (aortic valve area <1.0 cm2 or aortic valve
area index <0.6 cm2/m2, and either mean pressure
gradient >40 mm Hg or jet velocity >4 m/s). Patientstronic, and Siemens; and proctor fees from Edwards
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FIGURE 1 Lotus Aortic Valve Replacement System
The Lotus valve has 3 bovine pericardial tissue leaﬂets, a braided
nitinol frame, a central radiopaque marker to aid positioning, and
a polyurethane/polycarbonate outer seal designed to conform to
irregular anatomic surfaces and minimize paravalvular leak. The
braided structure shortens axially and expands radially during
implantation and is locked in position using a post-and-buckle
locking mechanism.
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1341were considered high risk for surgery on the basis of
a Society of Thoracic Surgery (STS) (v2.73) score $8%
(21) and/or coexisting comorbidities/frailty condi-
tions assessed by a local multidisciplinary heart team
(including a cardiac surgeon and an interventional
cardiologist). Patients had a documented aortic
annulus size $19 mm and #27 mm. Key anatomic
exclusion criteria included congenital unicuspid or
bicuspid aortic valve, pre-existing prosthetic heart
valve (aortic or mitral) or ring, mitral or aortic
regurgitation 3þ or greater, documented left ven-
tricular ejection fraction <30%, and femoral artery
lumen diameter <6.0 mm for the 23-mm valve
or <6.5 mm for the 27-mm valve. Key clinical exclu-
sion criteria included myocardial infarction within
30 days, transient ischemic attack or stroke within
the previous 6 months, severe renal insufﬁciency,
any therapeutic invasive cardiac procedure within
30 days, and cardiogenic shock or hemodynamic
instability. Complete inclusion and exclusion criteria
are provided in Online Appendix A.
The ethics committee at each participating center
approved the study, and all patients signed informedwritten consent before undergoing any study-speciﬁc
tests or procedures. Patients were screened by the
study centers and conﬁrmed eligible by a central case
review committee (which consisted of the study
principal investigator, other investigators experi-
enced with TAVR [including an experienced and
independent cardiac surgeon], and sponsor repre-
sentatives) (Online Appendix B). Data reviewed by
the case review committee included TTE, coronary
angiography, computed tomography (CT) angiog-
raphy of the aortic valve and entire aorta, and CT
angiography or invasive angiography of the iliofe-
moral system.
The principal method of determining aortic
annulus, left ventricular outﬂow tract (LVOT), and
trans-sinus dimensions was CT. The CT images from
all patients were analyzed by use of a pre-determined
standardized system (3mensio Medical Imaging BV,
Bilthoven, the Netherlands) and corroborated by an
independent core laboratory. Major and minor
diameters, perimeters, and areas were determined, as
were as the perimeter-derived diameter(s) and area-
derived diameter(s). This information was used to
select a valve size. Generally, the 23-mm valve was
used when the area-derived and perimeter-derived
annular diameters were less than 23 mm, and the 27
mm valve was used when the area-derived and
perimeter-derived annular diameters were between
23 and 27 mm. In borderline cases, the LVOT and
sinus dimensions, as well as the degree of calciﬁca-
tion, also inﬂuenced the choice of valve size.
To support the heart team’s assessment, the case
review committee reviewed the STS score, modiﬁed
Rankin Scale score, and comprehensive frailty
assessments (including grip strength, 5-meter gait
speed, Katz Index, Charlson Comorbidity Index Score,
and Mini-cognitive Assessment for Dementia) (22).
Patients were considered enrolled once an attempt
was made to insert the valve system into the femoral
artery.
PROTOCOL. All operators and medical personnel
completed comprehensive training before they
implanted valves in patients and received on-site
proctorship during implantation procedures from a
trained proctor experienced in TAVR. This study did
not have a roll-in patient phase. Patients were
prepared for the percutaneous procedure according
to standard techniques. The Lotus Introducer sheath
(outer diameter the same size as a conventional 18-F
[23-mm valve] or 20-F [27-mm valve] sheath) was
introduced through the femoral and iliac arterial
system and positioned in the descending aorta under
ﬂuoroscopic guidance, in accordance with standard
transfemoral TAVR techniques. Once all arterial and
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1342venous access was established, anticoagulation was
achieved with intravenous unfractionated heparin
with a target activated clotting time of $250 s.
A manually shaped super-stiff guidewire was
advanced across the aortic valve and positioned in
the left ventricle, typically in a right anterior oblique
ﬂuoroscopic projection. After standard balloon
valvuloplasty, the valve was positioned in the aortic
valve annulus. Rapid ventricular pacing was not
performed during valve implantation. In brief,
appropriate valve positioning was achieved by posi-
tioning the radiopaque central valve marker over a
predetermined landing plane. The position was
assessed by continuous ﬂuoroscopy, transesophageal
echocardiography, and/or contrast aortography dur-
ing controlled manual expansion, and the valve was
repositioned, if necessary, before ﬁnal release. Minor
repositioning was accomplished through partial valve
recapture; full recapture facilitated removal of the
valve if a different valve size was needed. Detailed
descriptions of the valve implantation procedure,
including full resheathing and retrieval of a valve
to facilitate a change in prosthesis size, have been
published (23,24).
A neurologist formally assessed all patients before
and after TAVR. After hospital discharge, clinical
follow-up was scheduled for 30 days, 3 months,
6 months, 12 months, and then annually from 2 to
5 years. Loading doses of aspirin (75 to 325 mg) and
clopidogrel ($300 mg) were required for patients who
had not been taking these medications for $72 h.
After the procedure, daily aspirin ($75 mg) was
required for at least 1 month and recommended
indeﬁnitely; clopidogrel (75 mg) once a day was
required for at least 1 month.
DATA MANAGEMENT. Study monitors veriﬁed all
case report form data on site. Clinical, imaging, and
pathology data were independently assessed by core
laboratories (Harvard Clinical Research Institute,
Peter J. Zimetbaum, Director [electrocardiography];
Beth Israel Deaconess Medical Center, Jeffrey J.
Popma, Director [angiography and CT/radiography];
MedStar, Neil J. Weissman, Director [echocardio-
graphy]; CVPath Institute, Renu Virmani, Director
[pathology]). An independent clinical events com-
mittee, including cardiothoracic surgeons, interven-
tional cardiologists, and a neurologist, adjudicated
adverse events. Committee members, institutions,
and research organizations participating in REPRISE II
are listed in Online Appendix B.
ENDPOINTS AND ADDITIONAL MEASUREMENTS.
The primary device performance endpoint was mean
aortic valve pressure at 30 days, which was comparedwith a pre-speciﬁed performance goal (PG) (see Sta-
tistical Methods). The primary safety endpoint was
30-day all-cause mortality. Additional pre-speciﬁed
measurements at clinical follow-up were based on
Valve Academic Research Consortium (VARC) end-
points and deﬁnitions (25,26). Valve performance was
assessed by TTE, functional status by NYHA class and
5-m gait speed, and health status by SF-12 and EQ-5D
quality-of-life questionnaires (22,27,28). Endpoints
and measurements are listed in Online Appendix C,
and major endpoint deﬁnitions are listed in Online
Appendix D.
STATISTICAL METHODS. The primary device perfor-
mance endpoint, mean aortic valve gradient at
30 days, was compared with a predeﬁned PG of
18 mm Hg (expected gradient of #15 mm Hg plus a
test margin of 3 mm Hg) on the basis of published
reports of outcomes with the Medtronic CoreValve
System and the Edwards Lifesciences’ SAPIEN
Transcatheter Heart Valve System (29–37). The alpha
level was adjusted for multiple analyses (2 interim
analyses of the ﬁrst 40 and 60 patients and 1 ﬁnal
analysis) on the basis of the Pocock alpha spending
function (38), and the data were compared using a
1-sample Student t test. Assuming an expected rate
of #15 mm Hg and a sample of $49 patients, the study
had $80% power to conclude that the valve mean
aortic gradient was less than the PG if the p value
from the 1-sample Student t test on the ﬁnal cohort
(n ¼ 120) was <0.01305. This corresponds to the
1-sided upper 98.695% conﬁdence bound of the
observed 30-day mean aortic valve gradient being <18
mm Hg. No statistical testing was performed for the
primary safety endpoint or the other endpoints. Sub-
ject demographics, clinical history, risk factors, de-
vice performance, and safety outcomes were
summarized using descriptive statistics for contin-
uous variables and frequency tables for discrete var-
iables. The p values are from the Student t test for
continuous variables (2-sided), Wilcoxon signed rank
test for paired data for comparison of NYHA class
distribution, and the repeated-measures and random
effects analysis of variance between-groups model for
the comparison of repeated measures such as mean
aortic gradient. All statistical analyses were per-
formed with SAS software (version 9.2 or above, SAS
Institute, Inc., Cary, North Carolina).
RESULTS
PATIENTS. There were 120 patients enrolled at 14
investigative centers in Australia, France, Germany,
and the United Kingdom between October 8, 2013, and
April 18, 2013 (Online Appendix B). Because existing
Intent-To-Treat (N=120)
30-Day F/U Data Available or Death Within
30 Days 99.2% (119/120)
Lotus Valve Implanted (N=120)
Death Within 30 Days (N=5)
No Lotus Valve Implanted (N=0)
No 30-Day F/U Data (N=1)
Withdrew Consent: 1
30-Day Echocardiograms Evaluable
by Core Lab: N=103
FIGURE 2 Patient Flow
A total of 120 patients were enrolled in REPRISE II (REpositionable Percutaneous
Replacement of Stenotic Aortic Valve Through Implantation of Lotus Valve System:
Evaluation of Safety and Performance). F/U ¼ follow-up.
TABLE 2 Procedural Outcomes
Successful access, delivery, deployment, system retrieval 100.0 (120/120)
Successful valve repositioning, if attempted (n ¼ 32)* 100.0 (32/32)
Partial valve resheathing, n 26
Full valve resheathing, n 6
Successful valve retrieval, if attempted (n ¼ 6)† 100.0 (6/6)
Aortic valve malpositioning 0.0 (0/120)
Valve migration 0.0 (0/120)
Valve embolization 0.0 (0/120)
Ectopic valve deployment 0.0 (0/120)
TAV-in-TAV deployment 0.0 (0/120)
Absence of procedural mortality‡ 99.2 (119/120)
Correct positioning of 1 valve in proper location 100.0 (120/120)
Mean aortic valve gradient <20 mm Hg§ 95.3 (101/106)
Peak velocity <3 m/s 94.3 (100/106)
No moderate/severe prosthetic valve regurgitation 98.1 (104/106)
Indexed EOA >0.85 cm2/m2 (>0.7 for BMI $30 kg/m2) 60.7 (51/84)
Values are % (n/N) unless otherwise indicated. N ¼ 120 patients overall. *Data are for the last
valve attempted. †In 4 patients, a 23-mm valve was inserted, but assessment before valve release
indicated the valve was too small for the annulus, and the valve was fully retrieved and replaced
with a 27-mm valve. In 1 patient, because of the length of the procedure and subsequent concerns
about poor leaﬂet hydration, the investigator successfully replaced one 23-mm valve with
another. In another patient, extensive handling due to difﬁculty crossing a heavily calciﬁed
annulus led to wire replacement and replacement of a 27-mm valve with another 27-mm valve.
‡The single death was associated with cardiac perforation and tamponade. §All patients with a
mean gradient $20 mm Hg post-procedure received a 23-mm valve.
BMI ¼ body mass index; EOA ¼ effective oriﬁce area; TAV ¼ transcatheter aortic valve.
TABLE 1 Baseline Patient Characteristics, Frailty Assessments,
and Echocardiographic Assessments
Patient characteristics (n ¼ 120)
Age, yrs 84.4  5.3 (120)
Female 56.7 (68)
STS score (v2.73) (21) 7.1  4.6 (120)
euroSCORE 2011 (39) 6.9  5.8 (120)
Diabetes mellitus, medically treated 22.5 (27)
NYHA functional class III or IV 75.8 (91)
Coronary artery disease, history 54.2 (65)
Prior PCI 22.7 (27)
Prior CABG 20.8 (25)
Atrial ﬁbrillation, history 40.8 (49)
Porcelain aorta 4.5 (5)
Hostile chest/unfavorable chest wall anatomy 4.3 (5)
Peripheral vascular disease, history 14.2 (17)
Cerebrovascular accident, history 4.2 (5)
Transient ischemic attack, history 10.1 (12)
COPD, moderate or severe 16.7 (20)
Frailty assessments (n¼120)
5-m speed, s 9.2  6.7 (119)
Grip strength, maximal, kg 20.1  12.8 (120)
Katz index 5.7  0.9 (120)
Charlson Comorbidity Index score 2.6  1.8 (120)
Mini-Cognitive Assessment for Dementia 3.6  1.4 (120)
Echocardiographic assessments: core laboratory
(n ¼ 112)
Aortic valve area (effective oriﬁce area), cm2 0.7  0.2 (97)
Mean aortic valve gradient, mm Hg 46.4  15.0 (104)
Peak aortic valve gradient, mm Hg 76.5  23.6 (104)
Left ventricular ejection fraction 54.3  10.7 (61)
Aortic regurgitation, moderate or severe* 15.2 (17)
Mitral regurgitation, moderate or severe† 11.6 (13)
Values are mean  SD (n) or % (n). *2.7% were severe. †All were moderate.
CABG ¼ coronary artery bypass graft; COPD ¼ chronic obstructive pulmonary
disease; euroSCORE ¼ European System for Cardiac Operative Risk Evaluation;
NYHA ¼ New York Heart Association; PCI ¼ percutaneous coronary intervention;
STS ¼ Society of Thoracic Surgeons.
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1343surgical risk scores imperfectly characterize risk, the
local heart teams at the centers also considered other
comorbidities and patient frailty and conﬁrmed all
patients to be at high risk for surgery. Table 1 shows
baseline characteristics, frailty assessments, and
echocardiographic assessments for the 120 patients
in REPRISE II. Mean age was 84.4  5.3 years, 57%
were female, and 76% were NYHA functional class III
or IV. The mean STS score and euroSCORE (European
System for Cardiac Operative Risk Evaluation) II (39)
were 7.1  4.6% and 6.9  5.8%, respectively.
OUTCOMES. Patient ﬂow and procedural outcomes
are shown in Figure 2 and Table 2, respectively. A Lotus
valve was successfully implanted in all patients.
Resheathing was undertaken in 32 patients (26.7%).
Partial valve resheathing to facilitate minor reposi-
tioning and accurate ﬁnal placement was successful in
all 26 attempts, and full resheathing to recapture andretrieve the valve was successful in 6 of 6 attempts
(Table 2). There was no valve migration, embolization,
ectopic valve deployment, or transcatheter aortic
valve (TAV)-in-TAV deployment. One death occurred
during the index procedure because of cardiac perfo-
ration. Overall procedure and ﬂuoroscopy times were
98.8  39.2 min and 31.8  13.0 min, respectively, with
196.7  83.6 ml of contrast used. Pre-deployment
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46.4 ± 15.0
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1.6 ± 0.4
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1.7 ± 0.4
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11.5 ± 5.2
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Baseline to Dis.
Baseline to 30D
Dis. to 30D
P value*
<0.001
<0.001
<0.001
<0.001
0.21 0.33
Gradient EOA
FIGURE 3 Mean Aortic Gradient and EOA by Transthoracic Echocardiography
The core laboratory independently assessed the data; cohort mean values at each time
point include standard deviation. The p values are from the repeated-measures and
random effects analysis of variance between groups. 30D ¼ 30-day follow-up;
Dis. ¼ discharge; EOA ¼ effective oriﬁce area.
TABLE 3 Transthora
Outcome
Peak aortic velocity, cm
Peak aortic gradient,
mm Hg*
Mean aortic gradient,
mm Hg*
Effective oriﬁce area, c
LVEF, %
LV end-systolic volume
ml
LV end-diastolic volum
ml
Mitral regurgitation,
mod/sev†
Values are mean  SD (n) o
number of evaluable echo
baseline to 30 days (paired
otherwise, all were modera
LV ¼ left ventricular; LV
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1344aortography was not mandated by the study protocol
but was performed in all patients. Post-deployment
aortography was mandated per protocol and was per-
formed in all patients.
The primary device performance endpoint was
met, because the 30-day mean aortic valve pressure
gradient was 11.5  5.2 mm Hg with a 1-sided 98.695%cic Echocardiography Data
Baseline Discharge/7 Days 30 Days
/s* 4.30  0.67 (105) 2.30  0.42 (106) 2.25  0.48 (97)
76.54  23.56 (104) 22.12  7.98 (106) 21.30  9.26 (97)
46.42  14.96 (104) 12.05  4.35 (106) 11.45  5.20 (97)
m2* 0.67  0.21 (97) 1.59  0.44 (88) 1.67  0.43 (78)
54.34  10.70 (61) 52.89  9.26 (56) 54.88  8.69 (60)
, 44.05  23.56 (61) 46.30  23.75 (56) 44.73  20.98 (60)
e, 94.63  35.85 (62) 95.48  35.49 (56) 96.40  31.53 (60)
11.6 (13/112) 8.2 (9/110) 10.7 (11/103)
r % (number/sample size). The core laboratory independently assessed the data; the
cardiograms for each outcome is indicated. *Signiﬁcant change (p < 0.001) from
Student t test). †There was 1 case of severe mitral regurgitation at discharge/7 days;
te.
EF ¼ left ventricular ejection fraction; mod/sev ¼ moderate/severe.upper conﬁdence bound of 12.6 mm Hg, signiﬁcantly
below (p < 0.001) the PG of 18 mm Hg. Exclusion of
the 4 patients who had baseline site-reported values
below 40 mm Hg (gradient) or 4 m/s (jet velocity) did
not meaningfully change this conclusion. Among
patients with evaluable echocardiograms, 95.3% (101
of 106) had a 30-day mean gradient #20 mm Hg
(Table 2). Figure 3 shows mean aortic gradient and
effective oriﬁce area over time; changes were statis-
tically signiﬁcant from baseline to discharge and
30 days. Additional valve performance data were
determined by independent core laboratory analyses
of TTE outcomes (n ¼ 112 at baseline, n ¼ 110 at
discharge/7 days, n ¼ 103 at 30 days) and are shown in
Table 3 and Figure 4. PVR was absent or trace-level
in 83.6% of evaluable echocardiograms at 30 days;
1 patient (1.0%) had moderate regurgitation, and no
patient had severe regurgitation (Figure 4).
Table 4 shows VARC-deﬁned clinical safety
outcomes at 30 days. Mortality was 4.2%, and the
disabling stroke rate was 1.7%. New permanent
pacemakers were placed in 34 patients (28.6%).
Overstretch, deﬁned as the theoretical area of the
valve divided by the measured area of the annulus or
LVOT, as assessed by the CT core laboratory, was a
predictor of the need for permanent pacemaker
implantation (40). Of the patients who required
implantation of a new permanent pacemaker, 41%
had $10% annulus overstretch and 56% had $10%
LVOT overstretch (Table 5). In patients without a new
permanent pacemaker, 24% had $10% annular over-
stretch and 36% had $10% LVOT overstretch (40).
Although 75.9% of REPRISE II patients (91 of 120)
were NYHA functional class III (n ¼ 77) or IV (n ¼ 14) at
baseline, this distribution was signiﬁcantly improved
at 30 days (91.0% NYHA functional class I or II,
p < 0.001) (Figure 5).
DISCUSSION
Principal ﬁndings from the present analysis, repre-
senting the primary endpoint and additional 30-day
outcomes from the prospective, single-arm, multi-
center REPRISE II study of the Lotus valve for high-
surgical-risk patients with severe aortic stenosis,
were as follows: 1) Successful valve implantation was
achieved in all 120 patients; 2) the primary device
performance endpoint was met; 3) there were low
30-day mortality (4.2%) and disabling stroke (1.7%)
rates; 4) no valve embolization, ectopic valve
deployment, or TAV-in-TAV deployment occurred;
5) there was marked improvement in functional class;
and 6) there were very low rates of signiﬁcant PVR.
These results conﬁrm the safety and efﬁcacy of the
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FIGURE 4 Aortic Regurgitation
The core laboratory independently assessed the data. The number of echocardiograms
evaluable for aortic regurgitation is indicated for each time point. Post-dilation was not
allowed per protocol and was not performed in any patient.
TABLE 4 Clinical Outcomes at 30 Days
Outcome* Patients (N ¼ 119)†
All-cause mortality 4.2 (5)
Cardiovascular mortality 4.2 (5)
All stroke‡ 5.9 (7)
Disabling stroke 1.7 (2)
Nondisabling stroke 4.2 (5)
All-cause mortality and disabling stroke 5.9 (7)
Life-threatening/disabling bleeding 5.0 (6)
Major bleeding 17.6 (21)
Acute kidney injury (stage 2 or 3) 3.4 (4)
Periprocedural coronary obstruction (#72 h) 0.8 (1)§
Major vascular complications 2.5 (3)¶
Repeat procedure (surgery/interventional) for valve-related dysfunction 0.0 (0)
Cardiac tamponade #72 h 3.4 (4)
Myocardial infarction #72 h 3.4 (4)
Myocardial infarction >72 h 0.0 (0)
Hospitalization for valve-related symptoms or CHF 4.2 (5)
New permanent pacemaker 28.6 (34)
New-onset atrial ﬁbrillation 5.0 (6)
Prosthetic valve endocarditis, thrombosis, migration, embolization 0.0 (0)
Values are % (n). *Events were adjudicated by the clinical events committee. †One patient withdrew consent.
‡A neurologist assessed all patients before and after transcatheter aortic valve replacement. §In the 1 patient
adjudicated as having a coronary obstruction, the event was related to stent thrombosis that occurred during
balloon aortic valvuloplasty in a recently placed mid-left anterior descending artery stent. The valve was
deployed, coronary access was intact, and the stent thrombosis was treated successfully. ¶There were 2 major
vascular complications related to access site.
CHF ¼ congestive heart failure.
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aortic stenosis (Central Illustration).
REPRISE II is 1 of the ﬁrst TAVR studies to report
outcomes on the basis of both VARC-2 (26) and
VARC-1 (25) metrics. Although differences in baseline
characteristics and variability in endpoint assessment
make it challenging to compare results across
studies, REPRISE II outcomes were consistent with
VARC-based event rates reported with other TAVR
valves (8,10,41–44) and with results from large
national registries (45–47). Although the percentage
of subjects meeting the VARC-2 indexed effective
oriﬁce area criteria was 60.7% (Table 2), this result is
similar to the results reported by the echocardiogra-
phy core laboratory for the SAPIEN valve (56%) and
for the surgical valves (40%) in the PARTNER
(Placement of Aortic Transcatheter Valves) Cohort A
trial (48). The permanent pacemaker implantation
rate was higher than that seen with the Edwards
SAPIEN valve but similar to that reported for the
Medtronic CoreValve (49).
Several features of the valve were designed to
improve upon ﬁrst-generation devices. The Lotus
valve 1) functions early in deployment, which
minimizes the period of hemodynamic compromise
and enables more controlled deployment; 2) can be
recaptured and repositioned at any stage of the
deployment process, which facilitates accurate and
precise ﬁnal positioning or retrieval for resizing
(if necessary); and 3) can be evaluated in its ﬁnal, fully
functioning state and position before uncoupling and
release from the delivery system. This was illustrated
recently in a published case study in which a deployed
23-mm valve was replaced with a 27-mm valve
because of sizing mismatch (24). Repositioning and
retrieval were successful in all REPRISE II cases
attempted, and a single device was positioned
correctly in all patients. The stroke rate for patients in
whom repositioning was attempted was similar to that
in patients without repositioning attempts (p ¼ 0.67).
Implantation of the valve with its adaptive seal,
which was designed to occlude interstices between
prosthesis and the calciﬁc degenerative leaﬂet mate-
rial at the aorto-ventricular interface, resulted in low
levels of post-implantation aortic regurgitation. At 30
days, PVR determined by the independent core lab-
oratory according to VARC guidelines (26) was absent
in 78.4%, at trace levels in 5.2%, mild in 15.5%,
moderate in 1.0%, and severe in none of the patients.
Reported moderate or severe aortic regurgitation af-
ter TAVR has ranged from 6% to 21% (50), and an
increased rate of late deaths to 2 years has been seen
with even mild PVR (12). Regurgitation of grade 2 or
more at 30 days post-implantation of commerciallyavailable TAVR devices was also shown to be an in-
dependent predictor of 1-year mortality (16,47). The
current results with the Lotus valve compare favor-
ably to aortic regurgitation outcomes in the study of
TABLE 5 Pacemaker Implantation
Characteristic
Newly implanted pacemaker* 28.6 (34/119)
Baseline RBBB 17.6 (6/34)
New conduction disturbance post-valvuloplasty 41.2 (14/34)
LVOT overstretch $10%† 55.9 (19/34)
Annulus overstretch $10%† 41.2 (14/34)
Paced rhythm at 30 days 47.1 (16/34)
Indication
Third-degree atrioventricular block 30
New LBBB, symptomatic bradycardia 1
LBBB, EP study showing severe infranodal disease 2
Trifascicular block 1
Values are % (n/N) or n. *All new conduction disorders were apparent immediately
post-procedure in patients in whom a newly implanted permanent pacemaker was
required. †Overstretch was deﬁned as the nominal valve area divided by the LVOT
or annular area as assessed by the computed tomography core laboratory (40).
EP ¼ electrophysiology; LBBB ¼ left bundle block branch; LVOT ¼ left
ventricular outﬂow tract; RBBB ¼ right bundle branch block. Aortic valve dysfunction
Pressure overload on left ventricle (LV)
Compensatory mechanisms
LV hypertrophy decreases compliance
Impaired ability to fill LV
Increased LV diastolic pressure
Increased oxygen 
demand
Long term increased
pressure overwhelms
LV contractility
PATHOPHYSIOLOGY 
Degeneration, 
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rheumatic heart disease, 
infection and other 
congenital issues
Wear
and tear
Aortic
valve
Bicuspid aortic
valve 
Aortic valve leaflet
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the valve opening) 
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1346another repositionable valve (51), as well as with
other commercially available transcatheter valves
(7,16,35,45–47). The ability to reposition the valve
may also have contributed to low PVR.
Reported rates for early conduction abnormalities
and the need for pacemaker implantation after TAVR
have ranged from 3% to 8% with SAPIEN and 14% to
40% with CoreValve (49). In 2 recent reports, clinical100%
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FIGURE 5 NYHA Symptom Status
New York Heart Association (NYHA) functional status is shown
according to time point. By 30 days post-procedure, there were 5
deaths, and 1 patient had withdrawn from the study.
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MANAGEMENT OPTIONS
CENTRAL ILLUSTRATION Pathophysiology and
Management of Aortic Stenosis
Management options for patients with aortic stenosis who
are surgical candidates or nonsurgical candidates. ACE ¼
angiotensin-converting enzyme; LV ¼ left ventricle/left
ventricular. Source: Bonow et al. (1).
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: TAVR may
improve 1-year survival in selected patients who are unsuitable
for or at high risk of complications with surgical valve
replacement.
TRANSLATIONAL OUTLOOK: Additional clinical trials and
longer follow-up are needed to better understand the compar-
ative outcomes TAVR versus surgical valve replacement in lower-
risk patients with aortic valve disease.
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1347outcomes at 12 to 24 months were similar among
patients with periprocedural permanent pacemaker
implantation and those without (52,53). Pre-existing
conduction disease has been identiﬁed as a predic-
tor of permanent pacemaker implantation after TAVR
(54). In REPRISE II, baseline right bundle branch
block was more common among patients who
received new pacemakers than those who did not
(p ¼ 0.02) (40). Of the patients who required im-
plantation of a new permanent pacemaker, 56%
had $10% overstretch at the LVOT; 41% had $10%
overstretch at the annulus (40). Future availability of
additional Lotus valve sizes may reduce overstretch
and the need for permanent pacemaker implantation.
STUDY LIMITATIONS. Limitations of this study
include the relatively small sample size, absence of a
randomized control group, and the limited follow-up
duration currently available. Longer-term follow-up
of this study and the future REPRISE III randomized
controlled trial will address some of these limitations
and enable further evaluation of the safety and efﬁ-
cacy of this novel bioprosthetic aortic valve.
CONCLUSIONS
The present study demonstrates the safety and efﬁ-
cacy of the Lotus valve in patients at high surgical risk
with severe aortic stenosis. The valve could be posi-
tioned precisely and successfully with minimal PVRafter placement. These results suggest the differen-
tiated second-generation Lotus device will be a
valuable addition for TAVR.
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